8-K: ADC Therapeutics Reports Promising Q1 2025 Results Driven by ZYNLONTA and Pipeline Progress

ADC Therapeutics announced its Q1 2025 financial results, highlighting the potential of ZYNLONTA in combination with glofitamab and providing updates on its clinical trials and preclinical programs.

Summary

• ADC Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• ZYNLONTA generated net product revenues of $17.4 million, slightly lower than the $17.8 million in Q1 2024.
• License revenues and royalties increased significantly to $5.6 million, compared to $0.2 million in Q1 2024, including a $5.0 million milestone payment from Health Canada's approval of ZYNLONTA.
• Research and Development (R&D) expenses increased to $28.9 million from $25.7 million in the prior year, driven by spending on next-generation ADCs.
• Selling and Marketing (S&M) expenses decreased to $10.6 million from $11.4 million in the prior year.
• General & Administrative (G&A) expenses decreased to $10.0 million from $12.0 million in the prior year.
• The net loss for the quarter was $38.6 million, or $0.36 per share, compared to a net loss of $46.6 million, or $0.56 per share, in Q1 2024.
• Adjusted net loss was $24.0 million, or $0.22 per share, compared to $31.1 million, or $0.38 per share, in Q1 2024.
• As of March 31, 2025, cash and cash equivalents were $194.7 million, and the company expects its cash runway to extend into the second half of 2026.
• The LOTIS-7 trial evaluating ZYNLONTA plus glofitamab showed an overall response rate (ORR) of 95.5% and a complete response (CR) rate of 90.9% in r/r DLBCL patients.
• Enrollment of 40 patients has been reached in the LOTIS-7 dose expansion arm.
• LOTIS-5 remains on track to reach prespecified progression-free survival (PFS) events by the end of 2025.
• The Phase 1/2 ADCT-602 clinical trial is being discontinued.
• Preclinical data on exatecan-based ADCs targeting CLDN6, PSMA, and ASCT2 were highlighted at AACR 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical trial data and a solid cash runway, although there are some challenges and risks associated with the company's operations.

Positives

• Significant increase in license revenues and royalties due to ZYNLONTA's approval in Canada.
• Promising data from the LOTIS-7 trial showing high response rates for ZYNLONTA plus glofitamab.
• Advancement of the LOTIS-7 trial with the enrollment of 40 patients in the dose expansion arm.
• LOTIS-5 trial remains on track to reach prespecified PFS events.
• Decrease in net loss and adjusted net loss compared to the same period in the previous year.
• Cash runway extended into the second half of 2026.

Negatives

• Slight decrease in ZYNLONTA product revenues compared to Q1 2024.
• Increase in R&D expenses due to investment in next-generation ADCs.
• Discontinuation of the Phase 1/2 ADCT-602 clinical trial.

Risks

• Future LOTIS-7 clinical trial results may differ from the data presented at EHA and ICML.
• The timing of PFS events for LOTIS-5 and the results of the trial are uncertain.
• The company's ability to grow ZYNLONTA revenue in the United States is subject to market conditions.
• Partners' ability to commercialize ZYNLONTA in foreign markets and obtain regulatory approval is uncertain.
• The company's indebtedness and the restrictions imposed by such indebtedness could impact its activities.
• The company's ability to obtain financial and other resources for its activities is subject to market conditions.

Future Outlook

The company expects to provide an update on the LOTIS-7 trial in the second half of 2025 and expects LOTIS-5 to reach prespecified PFS events by the end of 2025, with topline data to follow.

Management Comments

• Ameet Mallik, Chief Executive Officer of ADC Therapeutics, stated that the company is encouraged by the promising LOTIS-7 abstract data, which they believe demonstrates the potential for ZYNLONTA plus glofitamab to be a best-in-class combination.

Industry Context

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), competing with other companies developing ADCs for hematologic malignancies and solid tumors. The LOTIS-7 data positions ZYNLONTA as a potential best-in-class combination therapy in the DLBCL market.

Comparison to Industry Standards

• The 95.5% ORR and 90.9% CR rate observed in the LOTIS-7 trial for ZYNLONTA plus glofitamab compare favorably to other combination therapies in relapsed/refractory DLBCL.
• For example, Polivy (polatuzumab vedotin) plus BR (bendamustine and rituximab) showed a CR rate of around 40% in a similar patient population.
• CAR-T therapies like Yescarta and Kymriah have shown higher CR rates, but also come with significant safety concerns and logistical challenges.
• The LOTIS-5 trial, evaluating ZYNLONTA plus rituximab, aims to provide a more convenient and potentially safer alternative to existing treatments in the 2L+ DLBCL setting.

Stakeholder Impact

• Shareholders: The positive clinical trial data and financial results could positively impact shareholder value.
• Patients: The promising data from the LOTIS-7 trial could lead to a new treatment option for patients with r/r DLBCL.
• Employees: The company's progress and financial stability could positively impact employee morale and job security.
• Partners: The company's success in clinical trials and commercialization could strengthen its relationships with partners.

Next Steps

• The company expects to provide an update on the LOTIS-7 trial in the second half of 2025.
• The company expects LOTIS-5 to reach prespecified PFS events by the end of 2025, with topline data to follow.
• Updated data from the LOTIS-7 trial will be presented at EHA2025 and ICML in June 2025.
• Data from the LOTIS-5 trial will be presented at EHA2025 in June 2025.

Key Dates

Keywords

ZYNLONTA, ADC Therapeutics, Antibody Drug Conjugates, DLBCL, LOTIS-7, LOTIS-5, Financial Results, Clinical Trials, Oncology, Hematologic Malignancies